5aaa - Revision history

OCA at 11:06, 10 January 2024

2024-01-10T11:06:27Z

← Older revision		Revision as of 11:06, 10 January 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AAA FirstGlance]. <br>		<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AAA FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=VGH:3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-(1-PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE'>VGH</scene></td></tr>		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.73Å</td></tr>
			<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=VGH:3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-(1-PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE'>VGH</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5aaa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5aaa OCA], [https://pdbe.org/5aaa PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5aaa RCSB], [https://www.ebi.ac.uk/pdbsum/5aaa PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5aaa ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5aaa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5aaa OCA], [https://pdbe.org/5aaa PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5aaa RCSB], [https://www.ebi.ac.uk/pdbsum/5aaa PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5aaa ProSAT]</span></td></tr>
	</table>		</table>

OCA at 04:47, 25 May 2023

2023-05-25T04:47:48Z

← Older revision		Revision as of 04:47, 25 May 2023
Line 3:		Line 3:
	<StructureSection load='5aaa' size='340' side='right'caption='[[5aaa]], [[Resolution\|resolution]] 1.73Å' scene=''>		<StructureSection load='5aaa' size='340' side='right'caption='[[5aaa]], [[Resolution\|resolution]] 1.73Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5AAA FirstGlance]. <br>		<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AAA FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=VGH:3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-(1-PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE'>VGH</scene~~></td></tr>~~		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=VGH:3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-(1-PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE'>VGH</scene></td></tr>
	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5a9u\|5a9u]], [[5aa8\|5aa8]], [[5aa9\|5aa9]], [[5aab\|5aab]], [[5aac\|5aac]]</td></tr>~~		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5aaa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5aaa OCA], [https://pdbe.org/5aaa PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5aaa RCSB], [https://www.ebi.ac.uk/pdbsum/5aaa PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5aaa ProSAT]</span></td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5aaa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5aaa OCA], [~~http~~://pdbe.org/5aaa PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5aaa RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5aaa PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5aaa ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
	[~~[http~~://www.uniprot.org/uniprot/ALK_HUMAN ALK_HUMAN]] Note=A chromosomal aberration involving ALK is found in a form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with NPM1. The resulting chimeric NPM1-ALK protein homodimerize and the kinase becomes constitutively activated. The constitutively active fusion proteins are responsible for 5-10% of non-Hodgkin lymphomas. Note=A chromosomal aberration involving ALK is associated with inflammatory myofibroblastic tumors (IMTs). Translocation t(2;11)(p23;p15) with CARS; translocation t(2;4)(p23;q21) with SEC31A. Note=A chromosomal aberration involving ALK is associated with anaplastic large-cell lymphoma (ALCL). Translocation t(2;17)(p23;q25) with ALO17. Defects in ALK are the cause of susceptibility to neuroblastoma type 3 (NBLST3) [MIM:[~~http~~://omim.org/entry/613014 613014]]. Neuroblastoma is a common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.<ref>PMID:18724359</ref> <ref>PMID:18923523</ref> <ref>PMID:18923525</ref> Note=The ALK signaling pathway plays an important role in glioblastoma, the most common malignant brain tumor of adults and one of the most lethal cancers. It regulates both glioblastoma migration and growth.		[https://www.uniprot.org/uniprot/ALK_HUMAN ALK_HUMAN] Note=A chromosomal aberration involving ALK is found in a form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with NPM1. The resulting chimeric NPM1-ALK protein homodimerize and the kinase becomes constitutively activated. The constitutively active fusion proteins are responsible for 5-10% of non-Hodgkin lymphomas. Note=A chromosomal aberration involving ALK is associated with inflammatory myofibroblastic tumors (IMTs). Translocation t(2;11)(p23;p15) with CARS; translocation t(2;4)(p23;q21) with SEC31A. Note=A chromosomal aberration involving ALK is associated with anaplastic large-cell lymphoma (ALCL). Translocation t(2;17)(p23;q25) with ALO17. Defects in ALK are the cause of susceptibility to neuroblastoma type 3 (NBLST3) [MIM:[https://omim.org/entry/613014 613014]. Neuroblastoma is a common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.<ref>PMID:18724359</ref> <ref>PMID:18923523</ref> <ref>PMID:18923525</ref> Note=The ALK signaling pathway plays an important role in glioblastoma, the most common malignant brain tumor of adults and one of the most lethal cancers. It regulates both glioblastoma migration and growth.
	== Function ==		== Function ==
	[~~[http~~://www.uniprot.org/uniprot/ALK_HUMAN ALK_HUMAN]] Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK.<ref>PMID:11387242</ref> <ref>PMID:11121404</ref> <ref>PMID:11278720</ref> <ref>PMID:11809760</ref> <ref>PMID:12107166</ref> <ref>PMID:12122009</ref> <ref>PMID:15226403</ref> <ref>PMID:15908427</ref> <ref>PMID:16317043</ref> <ref>PMID:17274988</ref> <ref>PMID:16878150</ref>		[https://www.uniprot.org/uniprot/ALK_HUMAN ALK_HUMAN] Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK.<ref>PMID:11387242</ref> <ref>PMID:11121404</ref> <ref>PMID:11278720</ref> <ref>PMID:11809760</ref> <ref>PMID:12107166</ref> <ref>PMID:12122009</ref> <ref>PMID:15226403</ref> <ref>PMID:15908427</ref> <ref>PMID:16317043</ref> <ref>PMID:17274988</ref> <ref>PMID:16878150</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 22:

	==See Also==		==See Also==
	*[[Tyrosine kinase\|Tyrosine kinase]]		*[[Tyrosine kinase 3D structures\|Tyrosine kinase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Human~~]]		[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	~~[[Category: Receptor protein-tyrosine kinase]]~~		[[Category: Brooun A]]
	[[Category: Brooun, A]]		[[Category: Deng Y]]
	[[Category: Deng, Y]]		[[Category: Liu W]]
	[[Category: Liu, W]]		[[Category: McTigue M]]
	[[Category: McTigue, M]]		[[Category: Stewart A]]
	[[Category: Stewart, A]]
	~~[[Category: Anaplastic lymphoma kinase]]~~
	~~[[Category: Inhibitor]]~~
	~~[[Category: Mutant]]~~
	~~[[Category: Receptor tyrosine kinase]]~~
	~~[[Category: Transferase~~]]

OCA at 12:56, 10 May 2019

2019-05-10T12:56:35Z

← Older revision		Revision as of 12:56, 10 May 2019
Line 1:		Line 1:

	==Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib==		==Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib==
	<StructureSection load='5aaa' size='340' side='right' caption='[[5aaa]], [[Resolution\|resolution]] 1.73Å' scene=''>		<StructureSection load='5aaa' size='340' side='right'caption='[[5aaa]], [[Resolution\|resolution]] 1.73Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AAA FirstGlance]. <br>		<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AAA FirstGlance]. <br>
Line 22:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 5aaa" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5aaa" style="background-color:#fffaf0;"></div>

			==See Also==
			*[[Tyrosine kinase\|Tyrosine kinase]]
	== References ==		== References ==
	<references/>		<references/>
Line 27:		Line 30:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
			[[Category: Large Structures]]
	[[Category: Receptor protein-tyrosine kinase]]		[[Category: Receptor protein-tyrosine kinase]]
	[[Category: Brooun, A]]		[[Category: Brooun, A]]

OCA at 07:29, 4 July 2018

2018-07-04T07:29:43Z

← Older revision		Revision as of 07:29, 4 July 2018
Line 3:		Line 3:
	<StructureSection load='5aaa' size='340' side='right' caption='[[5aaa]], [[Resolution\|resolution]] 1.73Å' scene=''>		<StructureSection load='5aaa' size='340' side='right' caption='[[5aaa]], [[Resolution\|resolution]] 1.73Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AAA FirstGlance]. <br>		<table><tr><td colspan='2'>[[5aaa]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AAA FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=VGH:3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-(1-PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE'>VGH</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=VGH:3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-(1-PIPERIDIN-4-YL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE'>VGH</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5a9u\|5a9u]], [[5aa8\|5aa8]], [[5aa9\|5aa9]], [[5aab\|5aab]], [[5aac\|5aac]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5a9u\|5a9u]], [[5aa8\|5aa8]], [[5aa9\|5aa9]], [[5aab\|5aab]], [[5aac\|5aac]]</td></tr>
Line 26:		Line 26:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
			[[Category: Human]]
	[[Category: Receptor protein-tyrosine kinase]]		[[Category: Receptor protein-tyrosine kinase]]
	[[Category: Brooun, A]]		[[Category: Brooun, A]]

OCA at 10:19, 3 August 2017

2017-08-03T10:19:09Z

← Older revision		Revision as of 10:19, 3 August 2017
Line 7:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5a9u\|5a9u]], [[5aa8\|5aa8]], [[5aa9\|5aa9]], [[5aab\|5aab]], [[5aac\|5aac]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5a9u\|5a9u]], [[5aa8\|5aa8]], [[5aa9\|5aa9]], [[5aab\|5aab]], [[5aac\|5aac]]</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5aaa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5aaa OCA], [http://pdbe.org/5aaa PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5aaa RCSB], [http://www.ebi.ac.uk/pdbsum/5aaa PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5aaa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5aaa OCA], [http://pdbe.org/5aaa PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5aaa RCSB], [http://www.ebi.ac.uk/pdbsum/5aaa PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5aaa ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==

OCA at 15:18, 20 June 2016

2016-06-20T15:18:39Z

@@ Line 1: / Line 1: @@
-The entry 5aaa is ON HOLD  until Paper Publication
+==Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib==
-Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A.
+Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.,Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec , 23. PMID:26698910<ref>PMID:26698910</ref>
-Description: Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
-[[Category: Mctigue, M]]
+<div class="pdbe-citations 5aaa" style="background-color:#fffaf0;"></div>
 [[Category: Stewart, A]]
-[[Category: Liu, W]]
+[[Category: Anaplastic lymphoma kinase]]
-[[Category: Deng, Y]]
+[[Category: Inhibitor]]
-[[Category: Brooun, A]]
+[[Category: Mutant]]

OCA at 12:12, 12 August 2015

2015-08-12T12:12:04Z

← Older revision		Revision as of 12:12, 12 August 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 5aaa is ON HOLD		The entry 5aaa is ON HOLD until Paper Publication

	Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A.		Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A.

OCA: Protected "5aaa" [edit=sysop:move=sysop]

2015-08-05T17:34:26Z

Protected "5aaa" [edit=sysop:move=sysop]

← Older revision	Revision as of 17:34, 5 August 2015
(No difference)

OCA: New page: '''Unreleased structure''' The entry 5aaa is ON HOLD Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A. Description: Structure of L1198F Mutant Human Anaplastic Lymphoma ...

2015-08-05T17:34:25Z

New page: '''Unreleased structure''' The entry 5aaa is ON HOLD Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A. Description: Structure of L1198F Mutant Human Anaplastic Lymphoma ...

New page

'''Unreleased structure'''

The entry 5aaa is ON HOLD

Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A.

Description: Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
[[Category: Unreleased Structures]]
[[Category: Mctigue, M]]
[[Category: Stewart, A]]
[[Category: Liu, W]]
[[Category: Deng, Y]]
[[Category: Brooun, A]]